Sight Sciences delivered a robust Q3 2025 with revenues of $19.9 million, driven by strong adoption of its interventional glaucoma technologies and exciting advancements in its dry eye treatment segment.
- Raised full-year 2025 revenue guidance to $76 million to $78 million, reflecting positive momentum.
- Achieved key reimbursements in the TearCare segment with new fee schedules in place for over 10 million Medicare-covered lives.
- Experienced sequential growth in Surgical Glaucoma revenue, indicating effective operational execution and market demand.
- Targeted commercialization efforts underway for TearCare, with a focus on expanding market access and customer advocacy among 6,500 potential adopters.
Community Discussion